CASE REPORT article
Front. Pediatr.
Sec. General Pediatrics and Pediatric Emergency Care
Volume 13 - 2025 | doi: 10.3389/fped.2025.1656227
Metronidazole-induced encephalopathy in a patient with acute myeloid leukemia type 2 and a literature review of the pediatric cases reports
Provisionally accepted
- Department of Pediatrics, First Hospital, Peking University, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Metronidazole exerts neurotoxic effects on the central nervous system, leading to rare pediatric cases of metronidazole-induced encephalopathy (MIE). Methods: This study reports a pediatric patient with MIE. The patient's clinical and neuroimaging data was collected and analyzed. A literature review of pediatric MIE cases reported up to June 2025 was conducted using PubMed, Embase, Web of Science, Cochrane Library, WanFang, and CNKI databases. Results: A 13-year-old female developed MIE after two courses of metronidazole with cumulative doses of 31.2 g and 37.6 g. Clinical manifestations included altered mental status, ophthalmoplegia, dysarthria, dysphagia, involuntary movements, dystonia, urinary retention, muscle weakness, and absent tendon reflexes. Brain MRI revealed T2W/FLAIR and DWI hyperintensities symmetrically involving the dentate nuclei, splenium of corpus callosum, basal ganglia, thalamus, midbrain, and pons. After discontinuing metronidazole and vitamin B1 therapy, the patient's symptoms gradually improved, though extrapyramidal symptoms persisted. Repeated brain MRI at 10 days after cessation showed lesions partially resolved. Literature review identified 18 pediatric MIE cases, totaling 19 cases including our case. Except for one infant case presenting with intermittent hypothermia, bradycardia, growth retardation, reduced activity, muscle weakness and hypotonia, the predominant neurological symptoms in the other 18 cases were ataxia (11/18), altered mental status (8/18), dysarthria (7/18), and epileptic seizures (5/18). Symmetric brain MRI lesions involving dentate nuclei (13/17), splenium of corpus callosum (9/17), midbrain (6/17), pons (5/17). Most patients (17/19) achieved complete clinical resolution and brain MRI improvement after metronidazole withdrawal. Conclusion: Pediatric MIE is rare and manifests with widespread neurological involvement, characterized by cerebellar dysfunction, altered mental status, and seizures. Brain MRI typically reveals symmetrical lesions in the dentate nuclei, splenium of corpus callosum, and midbrain. Timely drug discontinuation is critical for treatment, and most cases are reversible, though a few may leave neurological sequelae.
Keywords: metronidazole-induced encephalopathy, Metronidazole, encephalopathy, MRI, pediatric
Received: 29 Jun 2025; Accepted: 17 Sep 2025.
Copyright: © 2025 Zhao, Zhang, Zhang, Zhang and Bao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xinhua Bao, zwhang@pku.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.